Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIS416 in Secondary Progressive Multiple Sclerosis
NCT02228213Phase 2Completed
- Sponsor
- Amplia Therapeutics Limited
- Start
- Oct 2014
- Primary completion
- May 2017
- Modality
- Nanoparticles
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of mis416 in secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by Amplia Therapeutics Limited. Primary endpoints: Change from baseline of neuromuscular function at 12 months and Proportion of Participants with Serious and Non-Serious Adverse Events at 12 months. Started Oct 2014; status: completed.
02
Drugs
mis416
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT02228213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228213.